Assistant Professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- thielen@eshpm.eur.nl
More information
‹ Back to overview
Profile
- W.F. Thielen, A. van Dongen-Leunis, A.M.M. Arons, J.R. Ladestein & P.R. Hoogerbrugge (2020). Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view. European Journal of Haematology. doi: 10.1111/ejh.13427 [go to publisher's site]
- V. Nijenhuis, J. Brouwer, R. Delewi, R.S. Hermanides, W. Holvoet, C. Dubois, P. Frambach, B. De Bruyne, G. van Houwelingen, J. Van Der Heyden, P. Toušek, F. van der Kley, I. Buysschaert, C.E. Schotborgh, B. Ferdinande, P. van der Harst, J. Roosen, J. Peper, W.F. Thielen, L. Veenstra, D. Chan Pin Yin, M.J. Swaans, B.J.W.M. Rensing, A. van 't Hof, L. Timmers, J.C. Kelder, P. Stella, J. Baan & J. ten Berg (2020). Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. New England Journal of Medicine. doi: 10.1056/NEJMoa1915152 [go to publisher's site]
- W.F. Thielen, M.E. Houwing, M.H. Cnossen, I.A. al Hadithy-Irgiztseva, J.A. Hazelzet, C.A. Uyl - de Groot, P.J. de Pagter & H.M. Blommestein (2020). Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. Pediatric Blood & Cancer, 67 (9):e28588. doi: 10.1002/pbc.28588
- B. Wijnen, W.F. Thielen, S. Konings, T. Feenstra, M. van der Gaag, W. Veling, L. De Haan, H. Ising, M. Hiligsmann, S.M.A.A. Evers, F. Smit & J. Lokkerbol (2019). Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. Expert review of pharmacoeconomics & outcomes research. doi: 10.1080/14737167.2019.1632194
- W.F. Thielen, H.M. Blommestein, L.E.M. Oosten, F.G. Calkoen, A.C. Lankester, J. Zwaginga, K. Le Blanc, A. Redondo, F. Sánchez‐Guijo, M. Algeri, F. Locatelli, W.E. Fibbe & C.A. Uyl - de Groot (2018). Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model. European Journal of Haematology, 101 (5), 676-683. doi: 10.1111/ejh.13158 [go to publisher's site]
- L.E.M. Oosten, M. Chamuleau, W.F. Thielen, L.C. de Wreede, C. Siemes, J.K. Doorduijn, O.S. Smeekes, M. Kersten, L. Hardi, J.W. Baars, A.M.P. Demandt, W. Stevens, G.W. Nijland, C.A. de Uyl-de Groot, P.M. Kluin, D. de Jong & H. Veelken (2018). Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Annals of Hematology, 97 (2), 255-266. doi: 10.1007/s00277-017-3167-7 [go to publisher's site]
- W.F. Thielen, N.C. Büyükkaramikli, R. Riemsma, D. Fayter, N. Armstrong, C. Wei, V. Huertas Carrera, K. Misso, G. Worthy, J. Kleijnen & I. Corro Ramos (2018). Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0740-4 [go to publisher's site]
- W.F. Thielen, G. van Mastrigt, L.T. Burgers, W.M. Bramer, H.J.M. Majoie, S.M.A.A. Evers & J. Kleijnen (2016). How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Expert review of pharmacoeconomics & outcomes research, 16 (6), 1-17. doi: 10.1080/14737167.2016.1246962
- W.F. Thielen, M. Ten Have, R. De Graaf, P. Cuijpers, A. Beekman & S.M.A.A. Evers (2016). Long-term economic consequences of child maltreatment: a population-based study. European Child & Adolescent Psychiatry, 1-9. doi: 10.1007/s00787-016-0850-5
- W.F. Thielen, H.M. Blommestein & C.A. de Uyl-de Groot (2016). Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease. Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110. doi: 10.1016/j.bbmt.2016.08.022
- K. Ruggeri, J.P. Stuhlreyer, J. Immonen, S. Mareva, A.F. Paul, A. Robbiani, W.F. Thielen, A. Gelashvili, F. Cavassini & F. Naru (2018). Policy evaluation. In K. Ruggeri (Ed.), Behavioral Insight for Public Policy: Concepts and Cases (pp. 3). New York: Routledge
- W.F. Thielen (2016). Entering your heart: how barely tested medical innovations find their way into clinical practice. In M.T. Brancaccio (Ed.), Governance of Health Care Innovation. Excursions into Politics, Science and Citizenship (pp. 19-40). Maastricht: Creative Commons License CC BY-NC
- W.F. Thielen (2018). Best Student Poster Presentation. Wetenschappelijk.
- W.F. Thielen (2020, december 16). Current Challenges in Health Technology Assessment: Assessing costs and cost-effectiveness of novel treatments in haemato-oncology. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & dr. H.M. Blommestein.
TriData
- Start date approval
- Feb/2021
- End date approval
- Jan/2024
- Place
- UTRECHT
- Description
- Teacher Statistical Programming & Data Science
Master Thesis Eu-HEM
- Title
- Master Thesis Eu-HEM
- Year
- 2020
- Year level
- master
Master Thesis HEPL
- Title
- Master Thesis HEPL
- Year
- 2020
- Year level
- master
Master Thesis HE
- Title
- Master Thesis HE
- Year
- 2020
- Year level
- master, master
Health Technology Assessment
- Title
- Health Technology Assessment
- Year
- 2020
- Year level
- master, master, master
Health Technology Assessment (Eu-HEM)
- Title
- Health Technology Assessment (Eu-HEM)
- Year
- 2020
- Year level
- master
Master HEPL-HE 2020-2021
- Title
- Master HEPL-HE 2020-2021
- Year
- 2020
Advanced Health Economic Modelling
- Title
- Advanced Health Economic Modelling
- Year
- 2020
- Year level
- master, master, master
Pharmaceutical Pricing and Market Access
- Title
- Pharmaceutical Pricing and Market Access
- Year
- 2020
- Year level
- master, master, master, master
Advanced Health Economic Modelling EuHEM
- Title
- Advanced Health Economic Modelling EuHEM
- Year
- 2020
- Year level
- master
Assistant Professor
- University
- Erasmus University Rotterdam
- School
- Erasmus School of Health Policy & Management
- Department
- Health Technology Assessment (HTA)
- Country
- The Netherlands